

Evidence. Engagement. Impact.



European Monitoring Centre for Drugs and Drug Addiction



AT THE HEART OF THE MATTER, NZ DRUG FOUNDATION. Te Tuäpapa Tarukino o Aotearoa

Third International Symposium on Drug-Impaired Driving

# Drug level and impairment – how do we measure this

Mário Dias

National Institute of Legal Medicine and Forensic Sciences

Lisbon, 23 October 2017







AT THE HEART OF THE MATTER, NZ DRUG FOUNDATION. Te Tuäpapa Tarukino o Aotearca

Lisbon, 23 October 2017

### Summary:

- Introduction
- Economic and Social Impact of Road Accidents
- Prevalence of Cannabis use
- DUID: Impairment vs Zero Tolerance
- Rate of prosecutions
- Conclusions



European Monitoring Centre for Drugs and Drug Addiction





Lisbon, 23 October 2017



Drug level and impairment - how do we measure this

Mário Dias



European Monitoring Centre for Drugs and Drug Addiction





Lisbon, 23 October 2017

### **P**REVALENCE OF **C**ANNABIS IN THE GENERAL POPULATION



**DISTRIBUTION BY AGE GROUPS** 

Drug level and impairment - how do we measure this

Mário Dias



European Monitoring Centre for Drugs and Drug Addiction





Lisbon, 23 October 2017

#### **PREVALENCE OF CANNABIS AMONG INJURED DRIVERS**





European Monitoring Centre for Drugs and Drug Addiction





Lisbon, 23 October 2017

### PREVALENCE OF CANNABIS AMONG INJURED DRIVERS







European Monitoring Centre for Drugs and Drug Addiction





Lisbon, 23 October 2017

### PREVALENCE OF CANNABIS AMONG INJURED DRIVERS





(Source: INMLCF)

Drug level and impairment – how do we measure this

Mário Dias



European Monitoring Centre for Drugs and Drug Addiction





Lisbon, 23 October 2017

Portaria 902-B/2007

# Article 22

1 - The <u>blood confirmation test</u> is intended to identify the substance or substances and or its metabolites that in the screening test showed positive results.

# Article 23

The **confirmation test** is considered **positive** whenever reveals the presence of any psychotropic substances (Table 1 of Annex V) or other substance or product, with similar effect, able to disturb the physical, mental or psychological conditions for driving motor vehicle safely.



Group	Substance
Cannabinoids	∆9 Tetrahydrocannabinol (THC) 11-hidroxy-∆9 Tetrahydrocannabinol (11-OH-THC) 11-Nor-9-Carboxy-∆9 Tetrahydrocannabinol (THC-COOH)
Opiates	Morphine 6 Monoacetylmorphine (6MAM)
Cocaíne e metabolites	Cocaíne Benzoilecgonine
Amphetamines	Amphetamine Metamphetamine 3,4-methylenodioxyamphetamine (MDA) 3,4-methylenodioxymethamphetamine (MDMA) 3,4-methylenodioxyethamphetamine (MDE;MDEA) 3,4-methylenodioxyphenyl-2-butamine (MBDB)









Lisbon, 23 October 2017



# Article 134

1 - If the same circumstances <u>simultaneously constitute a criminal and administrative</u> <u>offense, the driver shall always be punished by way of crime</u>, without prejudice to the application of the accessory penalty for the administrative offense.

### Código Penal

# Article 292

2 - Incurs in the same penalty who, at least negligently, drive a vehicle, with or without motor on public roads, <u>not being able to do it safely for being under the influence of narcotic drugs, psychotropic substances or similar products with physical, mental or psychological disturbing effect on fitness to drive</u>





Drug level and impairment – how do we measure this Mário Dias



European Monitoring Centre for Drugs and Drug Addiction



AT THE HEART OF THE MATTER. NZ DRUG FOUNDATION. Te Tuäpapa Tarukino o Aotearca

Lisbon, 23 October 2017



# How to interpret the analytical results in impairment approach?







AT THE HEART OF THE MATTER. NZ DRUG FOUNDATION. Te Tuäpapa Tarukino o Aotearca

Lisbon, 23 October 2017

*Per-se* approach can be based in three different type of limits:

- The lowest limit of quantification or limit of detection (Zero Tolerance)
- The lowest limit of impairment
- The lower limit of risk



European Monitoring Centre for Drugs and Drug Addiction



AT THE HEART OF THE MATTER. NZ DRUG FOUNDATION. Te Tuäpapa Tarukino o Aotearca

Lisbon, 23 October 2017



THC LEVEL IN BLOOD

Canadian Centre on Substance Use and Addiction

European Monitoring Centre
for Drugs and Drug Addiction



AT THE HEART OF THE MATTER. NZ DRUG FOUNDATION. Te Tuäpapa Tarukino o Aotearoa

Lisbon, 23 October 2017



### THC LEVEL IN BLOOD

(Source: INMLCF)

Drug level and impairment – how do we measure this Mário Dias



European Monitoring Centre for Drugs and Drug Addiction



AT THE HEART OF THE MATTER. NZ DRUG FOUNDATION. Te Tuäpapa Tarukino o Aotearoa

Lisbon, 23 October 2017

Prosecuted [Mean] = 2,81 [0,25 -17]

Not prosecuted [Mean] = 2,3 [0,25 - 10]

### THC LEVEL IN BLOOD





European Monitoring Centre for Drugs and Drug Addiction





Lisbon, 23 October 2017

# **KEY ISSUES**

- The presence of THC in blood affects the ability to drive
- There is a relationship between the concentration of THC in the blood and the degree of impairment, the risk of accident and culpability

 There is no agreement about the concentration of THC in blood that allows to distinguish the type of consumer and the moment of the last consume, despite several scientific studies

The approach to driving under the influence of drugs should be made in a road safety perspective

- The consumption of illicit substances, being an individual option, has social and economic consequences for all road users and for the society
- Increases the public perception of the likelihood that drug drivers would be convicted
- Monitor the drug driving problem and updates the legal limits according to the scientific literature and guidelines